Contact
leonard.moise@uga.edu
Education
PhD, Biochemistry, Brown University
ScB, Biochemistry, Brown University
Affiliation
Director of Vaccine Rsearch, EpiVax
Research Interest
Dr. Moise currently focuses on T-cell epitope-driven vaccine development using a genomes-to-vaccine approach that combines immunoinformatic and immunologic methods. Additionally, his research efforts comprise de-immunization of protein therapeutics by epitope modification.
Lab Focus
Vaccine development and therapeutics
Recent Publications
Hoffmann PR, Hoffmann FW, Premeaux TA, Fujita T, Soprana E, Panigada M, Chew GM, Richard G, Hindocha P, Menor M, Khadka VS, Deng Y, Moise L, Ndhlovu LC, Siccardi A, Weinberg AD, De Groot AS, Bertino P. 2019. Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models. Front. Oncol. Aug 2;9: 720. PMID:31428586
De Groot AS, Moise L. Innovation, urgency and acceptance at the 9th Vaccine Renaissance. Hum Vaccin Immunother. 2016 Dec;12(12):3186-3188. PMID: 28010520
Johnson H, Moise L, Menge A, Beseme S, De Groot AS. 8th vaccine renaissance: A creative nexus for vaccine developers. Hum Vaccin Immunother. 2015;11(9):2294-5. PMID: 26158225
Hoffmann PR, Panigada M, Soprana E, Terry F, Bandar IS, Napolitano A, Rose AH, Hoffmann FW, Ndhlovu LC, Belcaid M, Moise L, De Groot AS, Carbone M, Gaudino G, Matsui T, Siccardi A, Bertino P. Preclinical development of HIvax: Human survivin highly immunogenic vaccines. Hum Vaccin Immunother. 2015;11(7):1585-95. PMID: 26042612
PubMed
To be Announced.